JP5769923B2 - レストレスレッグス症候群の治療のためのラサギリンの使用 - Google Patents

レストレスレッグス症候群の治療のためのラサギリンの使用 Download PDF

Info

Publication number
JP5769923B2
JP5769923B2 JP2009504260A JP2009504260A JP5769923B2 JP 5769923 B2 JP5769923 B2 JP 5769923B2 JP 2009504260 A JP2009504260 A JP 2009504260A JP 2009504260 A JP2009504260 A JP 2009504260A JP 5769923 B2 JP5769923 B2 JP 5769923B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
propargyl
acceptable salt
pharmaceutically acceptable
aminoindan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009504260A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534312A5 (enExample
JP2009534312A (ja
Inventor
ブラウグルンド、エラン
レビー、ルトー
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2009534312A publication Critical patent/JP2009534312A/ja
Publication of JP2009534312A5 publication Critical patent/JP2009534312A5/ja
Application granted granted Critical
Publication of JP5769923B2 publication Critical patent/JP5769923B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2009504260A 2006-04-03 2007-03-30 レストレスレッグス症候群の治療のためのラサギリンの使用 Expired - Fee Related JP5769923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78861706P 2006-04-03 2006-04-03
US60/788,617 2006-04-03
PCT/US2007/008261 WO2007117431A2 (en) 2006-04-03 2007-03-30 Use of rasagiline for the treatment of restless legs syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013087636A Division JP2013166772A (ja) 2006-04-03 2013-04-18 レストレスレッグス症候群の治療のためのラサギリンの使用

Publications (3)

Publication Number Publication Date
JP2009534312A JP2009534312A (ja) 2009-09-24
JP2009534312A5 JP2009534312A5 (enExample) 2010-05-13
JP5769923B2 true JP5769923B2 (ja) 2015-08-26

Family

ID=38581572

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009504260A Expired - Fee Related JP5769923B2 (ja) 2006-04-03 2007-03-30 レストレスレッグス症候群の治療のためのラサギリンの使用
JP2013087636A Pending JP2013166772A (ja) 2006-04-03 2013-04-18 レストレスレッグス症候群の治療のためのラサギリンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013087636A Pending JP2013166772A (ja) 2006-04-03 2013-04-18 レストレスレッグス症候群の治療のためのラサギリンの使用

Country Status (11)

Country Link
US (16) US8946300B2 (enExample)
EP (1) EP2007369A4 (enExample)
JP (2) JP5769923B2 (enExample)
CN (1) CN101442997B (enExample)
AU (1) AU2007235517B2 (enExample)
CA (1) CA2646250A1 (enExample)
IL (5) IL194328A (enExample)
MX (1) MX2008012781A (enExample)
NZ (1) NZ571591A (enExample)
WO (1) WO2007117431A2 (enExample)
ZA (1) ZA200808409B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
KR20140103356A (ko) 2005-02-23 2014-08-26 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
EP1954667B1 (en) * 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2008076315A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010013393A (es) 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2009154777A2 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
ES2655676T3 (es) * 2012-01-12 2018-02-21 Pharma Two B Ltd. Terapia de combinación con dosis fijas para tratar la enfermedad de Parkinson
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
ES2983441T3 (es) 2018-02-15 2024-10-23 Intrabio Ltd Acetil-leucina para su uso en el tratamiento de síndrome de las piernas inquietas

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513249A (en) 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5444095A (en) 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5767164A (en) 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
EP1052983A2 (en) 1998-01-27 2000-11-22 Thomas N. Thomas Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
EP1066038B1 (en) * 1998-03-27 2005-12-21 Pharmacia & Upjohn Company LLC Use of cabergoline in the treatment of restless legs syndrome
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US20040052843A1 (en) 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CA2477218A1 (en) 2002-02-27 2003-09-04 Teva Pharmaceutical Industries, Ltd. Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
JP2005060370A (ja) * 2003-07-25 2005-03-10 Kyowa Hakko Kogyo Co Ltd 医薬組成物
US7735024B2 (en) 2003-10-29 2010-06-08 Intel Corporation Methods and apparatus to provide a handheld pointer-based user interface
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
CN101098685A (zh) 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
ATE521343T1 (de) 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
KR20140103356A (ko) 2005-02-23 2014-08-26 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
EP1954667B1 (en) 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2006327254A1 (en) * 2005-12-20 2007-06-28 Cereuscience Ab Method and composition for treating and diagnosing restless legs syndrome
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101032474B (zh) 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2008076315A1 (en) 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
JP5425806B2 (ja) 2007-12-24 2014-02-26 シプラ・リミテッド プロパルギル化アミノインダン誘導体の合成方法
NZ586025A (en) 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
US20110117200A1 (en) 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
ES2389353T3 (es) 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
JP2011522892A (ja) 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2009154777A2 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
CA2727021A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
CN101606923B (zh) 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
US20100010098A1 (en) 2008-07-11 2010-01-14 Walter Elffrink Polymorphs of rasagiline hydrochloride
WO2010007181A2 (en) 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
US20100029987A1 (en) 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
US20110263719A1 (en) 2008-07-30 2011-10-27 Vinayak Gore Polymorphic form of rasagiline mesylate
EP2181980A1 (en) 2008-10-28 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of (R)-1-aminoindanes
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
TW201028257A (en) * 2009-01-16 2010-08-01 Pao-Fang Liu Three-stage valve switch structure
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
US20110015274A1 (en) 2009-07-20 2011-01-20 Ester Masllorens Llinas Form of an aminoindan mesylate derivative
AU2010274589A1 (en) 2009-07-23 2012-02-16 Alkem Laboratories Ltd. Oral pharmaceutical composition of rasagiline and process for preparing thereof
US20110130466A1 (en) 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
WO2012050971A2 (en) 2010-09-29 2012-04-19 Teva Pharmaceutical Industries Ltd. Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use
EA201390613A1 (ru) 2010-10-26 2013-11-29 Тева Фармасьютикал Индастриз Лтд. Обогащенный дейтерием расагилин
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
US20130089611A1 (en) 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
ES2655676T3 (es) 2012-01-12 2018-02-21 Pharma Two B Ltd. Terapia de combinación con dosis fijas para tratar la enfermedad de Parkinson
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Also Published As

Publication number Publication date
IL265866A (en) 2019-06-30
US20190142766A1 (en) 2019-05-16
IL234749A0 (en) 2014-11-30
US20160317471A1 (en) 2016-11-03
US20210023026A1 (en) 2021-01-28
US20190262284A1 (en) 2019-08-29
US12310929B2 (en) 2025-05-27
CN101442997B (zh) 2012-11-14
US20210137852A1 (en) 2021-05-13
CN101442997A (zh) 2009-05-27
US20180169038A1 (en) 2018-06-21
WO2007117431A3 (en) 2008-11-27
US20210251921A1 (en) 2021-08-19
JP2013166772A (ja) 2013-08-29
IL275890A (en) 2020-08-31
US8946300B2 (en) 2015-02-03
CA2646250A1 (en) 2007-10-18
NZ571591A (en) 2011-09-30
AU2007235517B2 (en) 2013-01-31
US20200323796A1 (en) 2020-10-15
JP2009534312A (ja) 2009-09-24
IL247850A0 (en) 2016-11-30
EP2007369A2 (en) 2008-12-31
US20190365674A1 (en) 2019-12-05
US20210386690A1 (en) 2021-12-16
MX2008012781A (es) 2008-10-14
US20200206161A1 (en) 2020-07-02
US20070232700A1 (en) 2007-10-04
US20200093758A1 (en) 2020-03-26
ZA200808409B (en) 2009-12-30
US20150080441A1 (en) 2015-03-19
WO2007117431A2 (en) 2007-10-18
EP2007369A4 (en) 2009-07-01
US20170360723A1 (en) 2017-12-21
IL194328A (en) 2017-11-30
US20190000780A1 (en) 2019-01-03
AU2007235517A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
JP5769923B2 (ja) レストレスレッグス症候群の治療のためのラサギリンの使用
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
CN101657193A (zh) 用于治疗纤维肌痛的屈昔多巴及其药物组合物
CN1303286A (zh) 卡麦角林在治疗多动腿综合征中的应用
JP2015134811A (ja) 線維筋痛症候群の長期治療のためのミルナシプラン
WO2013063289A1 (en) Pharmaceutical compositions for treating pain
JP2010524989A (ja) 関節炎における痛みの治療のためのタペンタドール
JP2009511606A (ja) エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
US20040115263A1 (en) Use of bupropion for treating restless legs syndrome
WO2008009663A1 (en) Treatment of pain
CN120302968A (zh) 用于治疗焦虑及相关病症的ulotaront
JP2005533786A (ja) 不穏下肢症候群を治療するためのドパミン部分作用剤の使用、並びに対応する医薬製剤
JP2023504876A (ja) 薬物組成物、キット及びその応用
HK40070462B (zh) 用於疼痛疾患的米氮平和替扎尼定组合
KR20200085730A (ko) 헤로인 의존성 및 물질 사용 장애에 대한 마진돌 치료
JP2007511577A (ja) （２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノールの使用
MX2008016225A (es) Preparaciones de combinacion que comprenden slv308 y l-dopa.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150624

R150 Certificate of patent or registration of utility model

Ref document number: 5769923

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees